Penn Medicine has one of the few benign hematology programs in the country selected to participate in the NHLBI K12 program.
Implemented in 2006, the program's purpose is to develop, implement, and evaluate multidisciplinary career development programs in non-malignant hematology that will equip new investigators with the knowledge and skills to address complex problems in blood diseases.
Hematologists in the Penn Blood Center and Penn Comprehensive Hemophilia Program (PCHP) are published experts in areas such as aging and hemophilia, new products for bleeding disorders, and:
- Orthopaedic outcomes in persons with hemophilia with and without inhibitors.
- Septic arthritis in males with hemophilia.
- Joint range of motion limitations.
- Physical therapy evaluation, intervention and recommendations.
- Educational attainment among persons with hemophilia.
- Effects of insurance on home therapy and prophylaxis.
- Pregnancy alternatives for HIV discordant couples.
Through research at Penn Medicine, patients have the opportunity to participate in clinical trials using innovative treatments for blood disorders.
Medical oncologists involved in the management of hemophilia include: